Recombinant Anti-Cdc6 antibody [EPR714(2)] (ab109315)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR714(2)] to Cdc6
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Cdc6 antibody [EPR714(2)]
See all Cdc6 primary antibodies -
Description
Rabbit monoclonal [EPR714(2)] to Cdc6 -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, WB, IHC-Pmore details
Unsuitable for: Flow Cyt (Intra) -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Hela, 293T, HCT116 treated with hydroxyurea and Raji treated with FBS lysates IHC-P: Human gastric adenocarcinoma, breast carcinoma, thyroid cancer tissue ICC/IF: HeLa
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR714(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab109315 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF | (2) |
1/100.
For unpurified use at 1/250 - 1/500 |
WB |
1/1000 - 1/10000. Detects a band of approximately 62 kDa (predicted molecular weight: 63 kDa).
|
|
IHC-P |
1/90. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
ICC/IF
1/100. For unpurified use at 1/250 - 1/500 |
WB
1/1000 - 1/10000. Detects a band of approximately 62 kDa (predicted molecular weight: 63 kDa). |
IHC-P
1/90. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Function
Involved in the initiation of DNA replication. Also participates in checkpoint controls that ensure DNA replication is completed before mitosis is initiated. -
Sequence similarities
Belongs to the CDC6/cdc18 family. -
Cellular localization
Nucleus. Cytoplasm. The protein is nuclear in G1 and cytoplasmic in S-phase cells. - Information by UniProt
-
Database links
- Entrez Gene: 990 Human
- Omim: 602627 Human
- SwissProt: Q99741 Human
- Unigene: 405958 Human
-
Alternative names
- Cdc 18L antibody
- Cdc 6 antibody
- CDC18 (cell division cycle 18, S.pombe, homolog) like antibody
see all
Images
-
All lanes : Anti-Cdc6 antibody [EPR714(2)] (ab109315) at 0.5 µg/ml (purified)
Lane 1 : 293T (Human embryonic kidney epithelial cell) whole cell lysates
Lane 2 : 293T (Human embryonic kidney epithelial cell) treated with 20mM Hydroxyurea for 24 hours whole cell lysates
Lane 3 : HCT116 (Human colorectal carcinoma epithelial cell) whole cell lysates
Lane 4 : HCT116 (Human colorectal carcinoma epithelial cell) treated with 1mM Hydtoxyurea for 16 hours whole cell lysates
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 63 kDaBlocking and diluting buffer: 5% NFDM/TBST.
Hydroxyurea induces Cdc6 expression (PMID:11346650) -
Immunocytochemistry/ Immunofluorescence analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labeling Cdc6 with Purified ab109315 at 1:100 dilution (9.4 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor®594) 1:200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor®488, ab150077) was used as the secondary antibody at 1:1000 (2 µg/ml) dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human thyroid cancer tissue sections labeling Cdc6 with Purified ab109315 at 1:90 dilution (10.4 µg/ml). Heat mediated antigen retrieval was performed using using ab93684 (Tris/EDTA buffer, pH 9.0)ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody.Negative control:PBS instead of the primary antibody.Hematoxylinwas used as a counterstain
-
Immunohistochemical analysis of Cdc6 in paraffin embedded Human gastric adenocarcinoma tissue, using unpurified ab109315 at a 1/1000 dilution.
-
Immunohistochemical analysis of Cdc6 in paraffin embedded Human breast carcinoma tissue, using unpurified ab109315 at a 1/1000 dilution.
-
Unpurified ab109315 staining Cdc6 in the Hela cell line from Human cervix by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with 0.5% Triton X-100. Samples were incubated with primary antibody (1/500 in PBS) for 1 hour at 22°C. Ab150081 (1/200) was used as the secondary antibody.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (16)
ab109315 has been referenced in 16 publications.
- Yang C et al. The Effect of High CDC6 Levels on Predicting Poor Prognosis in Colorectal Cancer. Chemotherapy 67:47-56 (2022). PubMed: 35034031
- Minet M et al. A Temporary Pause in the Replication Licensing Restriction Leads to Rereplication during Early Human Cell Differentiation. Cells 11:N/A (2022). PubMed: 35326512
- Huang Y et al. Human cytomegalovirus RNA2.7 inhibits RNA polymerase II (Pol II) Serine-2 phosphorylation by reducing the interaction between Pol II and phosphorylated cyclin-dependent kinase 9 (pCDK9). Virol Sin 37:358-369 (2022). PubMed: 35537980
- Yicong Y et al. Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Front Oncol 11:666418 (2021). PubMed: 34136398
- Kong DG & Yao FZ CDC6 is a possible biomarker for hepatocellular carcinoma. Int J Clin Exp Pathol 14:811-818 (2021). PubMed: 34367412